Naviscan scores PEM orders in the EU
Naviscan PET scanners performing positron emission mammography (PEM) have been installed in two European centers: Radiologie und Nuklearmedizin in Ludwigshafen, Germany, and Medica in Istanbul, Turkey.
These mark the first installations of a backlog of orders in the European market, according to the San Diego-based company. PEM imaging shows the location as well as the metabolic phase of a lesion, and this information can be used to determine whether a lesion is malignant and influence the course of treatment by providing an ability to distinguish between benign and malignant lesions, Naviscan said.
The scanner is an FDA-cleared, CE-certified 3D molecular breast imaging device with biopsy-guidance.
These mark the first installations of a backlog of orders in the European market, according to the San Diego-based company. PEM imaging shows the location as well as the metabolic phase of a lesion, and this information can be used to determine whether a lesion is malignant and influence the course of treatment by providing an ability to distinguish between benign and malignant lesions, Naviscan said.
The scanner is an FDA-cleared, CE-certified 3D molecular breast imaging device with biopsy-guidance.